Xilio Therapeutics (NASDAQ:XLO) Releases Quarterly Earnings Results, Beats Estimates By $0.26 EPS

Xilio Therapeutics (NASDAQ:XLO) posted its quarterly earnings data on Wednesday. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.26, FiscalAI reports. The company had revenue of $18.69 million during the quarter, compared to analysts’ expectations of $12.72 million. Xilio Therapeutics had a negative return on equity of 151.42% and a negative net margin of 58.52%.

Xilio Therapeutics Price Performance

NASDAQ XLO traded down $0.23 on Wednesday, hitting $8.95. 3,707 shares of the stock were exchanged, compared to its average volume of 40,686. The business’s fifty day moving average is $8.84 and its 200 day moving average is $8.36. Xilio Therapeutics has a 52 week low of $6.47 and a 52 week high of $12.74. The company has a market capitalization of $58.89 million, a PE ratio of -2.52 and a beta of -0.14.

Analyst Ratings Changes

Several research firms have commented on XLO. Weiss Ratings cut Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. Wall Street Zen downgraded shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On Xilio Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in Xilio Therapeutics in the 4th quarter valued at about $27,000. Velan Capital Investment Management LP bought a new position in Xilio Therapeutics during the fourth quarter worth about $109,000. State Street Corp increased its position in Xilio Therapeutics by 13.7% during the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after buying an additional 22,500 shares during the last quarter. Renaissance Technologies LLC increased its position in Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after buying an additional 139,716 shares during the last quarter. Finally, Squarepoint Ops LLC raised its stake in Xilio Therapeutics by 39.6% in the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock valued at $277,000 after buying an additional 93,338 shares during the period. 54.29% of the stock is owned by institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.